Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Swidnica – page 31

985 clinical trials in Swidnica, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Swidnica at a glance
985
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

985 trials in Swidnica

Open in trial search

Plasma cell myeloma

Not yet recruiting

A Phase III Study of AZD0120 versus melphalan hydrochloride with lenalidomide maintenance in transplant‑eligible adults with newly diagnosed multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Safety and Efficacy of Extended‑Release Tacrolimus (VI‑0106) in Adults with Pulmonary Arterial Hypertension and Functional Limitations

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tacrolimus
  • Sponsor:Vivus B.V.

Acute myeloid leukaemia

Not yet recruiting

A Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Charm Therapeutics Limited

Myasthenia gravis

Not yet recruiting

Efficacy and Safety of DNTH103 in Adults with Generalized Myasthenia Gravis: A Phase 3 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Asthma

Not yet recruiting

Long‑Term Safety and Tolerability Study of Oral KT‑621 in Adults with Uncontrolled Moderate‑to‑Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Lichen sclerosus

Not yet recruiting

A Phase 3 Study of Delgocitinib Cream to Evaluate Efficacy and Safety in Adult Women with Lichen Sclerosus

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Delgocitinib
  • Sponsor:LEO PHARMA A/S

Plasma cell myeloma

Not yet recruiting

Reduced vs Standard Dose Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Phase II MRD‑Guided Study

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin
  • Sponsor:Polish Myeloma Consortium

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of venetoclax plus rituximab in adult patients with relapsed chronic lymphocytic leukemia (CLL) in Poland

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Chronic lymphocytic leukaemia+1

Not yet recruiting

Safety and efficacy of venetoclax, obinutuzumab and daratumumab in adult patients with relapsed chronic lymphocytic leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Uniwersytet Medyczny W Lublinie

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Swidnica

What the registry says about research in the country

01 Inflammatory Conditions

Innovative research focusing on inflammatory disorders, including trials evaluating new treatments for psoriatic arthritis and rheumatoid arthritis. Studies aim to assess novel therapeutic approaches using biologics and targeted medications.

  • Psoriatic Arthritis Studies
  • Rheumatoid Arthritis Treatment
  • Inflammatory Disease Management

Advanced therapies being tested to improve patient outcomes and quality of life.

02 Gastrointestinal Research

Comprehensive studies investigating treatments for inflammatory bowel diseases, including trials for Crohn's Disease and ulcerative colitis. Research focuses on novel therapeutic agents and long-term disease management.

  • Crohn's Disease Therapies
  • Ulcerative Colitis Treatments
  • Long-term Disease Management

Multiple trials exploring innovative approaches to treating gastrointestinal conditions.

03 Metabolic and Pain Management

Studies addressing obesity, knee osteoarthritis, and chronic pain conditions. Research includes evaluation of new medications for weight management and innovative approaches to pain relief.

  • Weight Management Therapies
  • Osteoarthritis Treatment
  • Pain Management Solutions

Cutting-edge research combining multiple therapeutic approaches for complex conditions.

04 Specialty Conditions

Focused research on unique conditions including thyroid eye disease, chronic spontaneous urticaria, and rotator cuff tendinopathy. Studies aim to develop targeted treatments for these specific medical needs.

  • Endocrine Disorders
  • Autoimmune Conditions
  • Musculoskeletal Treatments

Specialized therapeutic approaches for distinct medical conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.